This Clinical Reference Group (CRG) covers Haematopoietic Stem Cell Transplantation (HSCT) services. Also known as Blood and Marrow Transplantation (BMT), the intervention is used to treat a wide spectrum of haematological and, increasingly, non-haematological disorders. The most common clinical indications for HSCT are leukaemias, lymphomas and myeloma.
Services include all care provided by Specialist Transplantation Centres, including preparatory care, donation, transplant, aftercare and subsequent treatment covering 30 days before and 100 days after transplant. The service includes outreach when delivered as part of a provider network. This applies to provision in adults and children.
Chair: Professor John Snowden, Consultant Haematologist, Sheffield Teaching Hospitals NHS Foundation Trust.
Gordon Cook, North
Fiona Dignan, North
Charles Craddock, Midlands & East
Charles Crawley, Midlands & East
Tony Pagliuca, London
Jane Apperley, London
Hannah Hunter, South
Deborah Richardson, South
Giles Ratcliffe, PHE Lead
Nick Duncan, Pharmacy Lead
Gillian Adams, Patient & Public Voice
Orin Cadogan-Lewis, Patient & Public Voice
Mark Ritson, Patient & Public Voice
Rob Coster, Lead Commissioner, email@example.com
A key part of the CRG’s work is the delivery of the ‘products’ of commissioning. These are the tools used by the 10 Hub Commissioning Teams to contract services on an annual basis.
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.
The following service specifications fall within the scope of this CRG:
- Severe Combined Immunodeficiency and Related Disorders Service (children) – in partnership with the Women and Children’s NPOC
- Haematopoiec Stem Cell Transplantation (Adult)
- Haematopoietic Stem Cell Transplantation (Children)
- Paroxysmal Nocturnal Haemoglobinuria Service (Adults and Adolescents)
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies fall within the scope of this CRG:
- Allogeneic stem cell transplantation for adults with PID disorders
- Second allogeneic haematopoietic stem cell transplant for relapsed disease
- Haematopoietic Stem Cell Transplantation (HSCT) – lymphoplasmacytic lymphoma
- Haematopoietic Stem Cell Transplantation (HSCT) (All Ages)
- Use of Plerixafor for Stem Cell Mobilisation (Please note: This policy updates and replaces B04/PS/a Clinical commissioning policy statement: Use of Plerixafor for stem cell mobilisation)
- Use of Defibrotide in severe veno-occlusive disease
- Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation